Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19

Ju-Pi Li 1,2, Kang-Hsi Wu 2,3, Wan-Ru Chao 1,4, Yi-Ju Lee 1,4, Shun-Fa Yang 5,6 and Yu-Hua Chao 2,3,7,*

1 Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; d888203@gmail.com (J.-P.L.); littleuni@hotmail.com (W.-R.C.); jasmine.lyl@gmail.com (Y.-J.L.)
2 Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 402, Taiwan; cshy1903@gmail.com
3 Department of Pediatrics, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
4 Department of Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan
5 Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; ysf@csmu.edu.tw
6 Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan
7 Department of Clinical Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan
* Correspondence: chaoyuhua@yahoo.com.tw; Tel.: +886-4-24739595

Abstract: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major public health challenge worldwide. Owing to the emergence of novel viral variants, the risks of reinfections and vaccine breakthrough infections has increased considerably despite a mass of vaccination. The formation of cytokine storm, which subsequently leads to acute respiratory distress syndrome, is the major cause of mortality in patients with COVID-19. Based on results of preclinical animal models and clinical trials of acute lung injury and acute respiratory distress syndrome, the immunomodulatory, tissue repair, and antiviral properties of MSCs highlight their potential to treat COVID-19. This review article summarizes the potential mechanisms and outcomes of MSC therapy in COVID-19, along with the pathogenesis of the SARS-CoV-2 infection. The properties of MSCs and lessons from preclinical animal models of acute lung injury are mentioned ahead. Important issues related to the use of MSCs in COVID-19 are discussed finally.

Keywords: acute lung injury; acute respiratory distress syndrome; cell therapy; COVID-19; mesenchymal stem cells

1. Introduction

The outbreak of the coronavirus disease 2019 (COVID-19) pandemic, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as its causative pathogen, is quickly spreading and causing the collapse of healthcare systems worldwide. A vast majority of infected individuals have mild respiratory symptoms. However, approximately 15–20% of patients with COVID-19 develop severe or critically severe symptoms or complications, such as pneumonia, acute respiratory distress syndrome (ARDS), respiratory failure, sepsis and septic shock, multi-organ failure, and even death. The formation of cytokine storm is one of the hallmarks of COVID-19, and ARDS caused by cytokine storm is the major mortality factor in patients with COVID-19 [1]. In combination with traditional treatment of support care for viral diseases, a variety of strategies have been proposed to control cytokine storm in COVID-19. However, the mortality rate in critically severe patient remains high and an unmet medical need still exists for these patients.

Biologic interest in mesenchymal stem cells (MSCs), which was first described by Friedenstein et al. in 1966 [2], has risen dramatically. As is expected, clinical application of MSCs is evolving rapidly for a variety of human diseases. Along with a broad and
great immunomodulatory capacity, MSCs have antiviral activities and the potential to promote tissue repair. These properties signify their potential to treat COVID-19, especially to combat against cytokine storm.

Many aspects in pathogenesis and clinical manifestations of COVID-19 have certain similarities with infectious acute lung injury (ALI). Based on currently available results of preclinical models and stage-clinical trials of ALI and ARDS, MSC-based cell therapy is proposed as a promising option in the management of COVID-19. In this review article, we summarized the potential mechanisms of action and clinical outcomes of MSC therapy in COVID-19, along with the pathogenesis of the SARS-CoV-2 infection. The properties of MSCs, especially focusing on their immunomodulatory function, and lessons from preclinical animal models of ALI are mentioned ahead. Finally, important issues related to the application of MSCs in COVID-19 are discussed. We anticipate that more patients can benefit from the therapeutic effects of MSCs in the near future.

2. Properties of MSCs
2.1. Biologic Features of MSCs

According to the consensus statement by the International Society for Cellular Therapy in 2006, human MSCs must fulfill the minimum criteria for identification based on their in vitro growth pattern, the specific surface marker expression, and the multipotent differentiation potential [3]. With fibroblast-like morphology, MSCs must be plastic-adherent when maintained in standard culture conditions. MSCs must express CD105, CD73, and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR. MSCs must have the capacity for trilineage mesenchymal differentiation, including osteoblasts, adipocytes and chondroblasts (Figure 1).

![Figure 1. Common sources of MSCs and the minimum criteria for identification by the International Society for Cellular Therapy.](image)

2.2. Isolation of MSCs from Various Origins

MSCs are derived from mesodermal progenitor cells. They can be isolated from a broad spectrum of tissues (Figure 1), including adult tissues (bone marrow, peripheral blood, and adipose) and fetal tissues (cord blood, umbilical cord, placenta, and amniotic fluid). MSCs were originally identified in the bone marrow [2], and thus bone marrow is considered to be their traditional source. In fact, MSCs constitute a very small percentage, about one in $3.4 \times 10^4$ cells, in the bone marrow [4]. Considering efficacy and ethical issues of isolation, to find alternative cell sources with better availability is an important issue in modern cell-based therapy.

Umbilical cords are rich in MSCs which can be easily collected and cultured [5]. Most importantly, obtaining MSCs from umbilical cords is safe for both mother and baby without requiring an invasive and painful procedure. It is of interest that umbilical-cord-derived MSCs (UCMSCs) exhibit greater proliferative potential and shorter doubling
time in vitro [6], indicating a shorter amount of time needed to obtain sufficient cells for clinical use. Compared to their bone marrow counterpart, UCMSCs show higher immunomodulatory potential [6], suggesting that UCMSCs are more feasible for clinical diseases with aberrant immune responses. In addition, UCMSCs express lower levels of HLA-class I molecules [7], implicating less intensity of their immunogenicity and the superiority in clinical utility. Therefore, umbilical cords represent an appealing source of MSCs and should not be discarded as medical waste.

2.3. Immunomodulatory Properties of MSCs: Focus on Molecular Biology

MSCs exhibit profound immunomodulatory potential, and their effects are achieved via a number of signaling pathways and a network of complicated immune responses. MSCs have the capacity to interact with immune cells in both innate and adaptive immune systems. Mechanisms of interaction are dependent on cell-to-cell contact along with the release of a variety of soluble factors. With the expression of immunosuppressive ligands such as programmed cell death protein 1 (PD-1) and Fas-ligand on their surface, MSCs can bind receptors on the surface of immune cells and result in loss of function in immune cells [8,9]. MSCs can block the differentiation of monocytes into dendritic cells and impair their antigen-presenting ability [10]. The MSC-mediated inhibitory effects may be dependent on IL-6 and hepatocyte growth factor (HGF) secreted by MSCs, and this effect can induce monocyte-derived cells to produce IL-10, which might indirectly strengthen the suppressive effects of MSCs [11]. In addition, IL-1 receptor antagonist and CCL18 secreted by MSCs may participate in promotion of macrophage polarization from M1 to M2 phenotype, involving IL-10 secretion, regulatory T cell (Treg) generation, and the immunosuppression on CD4+ T cells [12,13].

MSCs act on the adaptive immune system in various ways. Through producing soluble factors, MSCs can inhibit B cell proliferation via arrest in the G0/G1 phase of the cell cycle [14]. Furthermore, MSCs can down-regulate B cell differentiation, chemotaxis to CXL12 and CXCL13, and immunoglobulin production [14]. MSCs influence the behavior of T cells significantly, including inhibition of proliferation, cytokine secretion, and cytotoxicity. By exposure to interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), MSCs can secrete PD-1 ligands and lead to the suppression of T cell activation [15]. Upon interaction with dendritic cells, MSCs can regulate the balance between Th1 and Th2 cells. Through secreting transforming growth factor-β1 (TGF-β1) and indoleamine 2,3-dioxygenase, MSCs can promote the generation of Tregs, which is one of the main features of MSC-mediated immune modulation [13,16]. MSCs can induce IL-10 and prostaglandin E2 (PGE2) production and inhibit IL-17, IL-22, and IFN-γ to limit Th17 differentiation [17]. MSCs also can suppress Th17 responses by modulating the IL-25/STAT3/PD-L1 axis [18]. Under inflammatory conditions, MSCs can mediate the adhesion of Th17 cells via CCR6 and exert anti-inflammatory effects through the induction of Tregs [17].

It is interesting to note that MSCs act like a double-edged sword in regulating the immune system. There is a dual effect of MSCs on immune reactions, and nitric oxide or indoleamine 2,3-dioxygenase may act as a switch in MSC-mediated immunomodulation [19]. As a consequence, MSCs can become highly immunosuppressive upon stimulation by inflammatory cytokines but can promote immune responses under low levels of IFN-γ and TNF-α [19]. On the other hand, MSCs express high levels of Toll-like receptors (TLRs) 3 and 4 on their surface, and ligation of TLR3 and TLR4 can inhibit the ability of MSCs to suppress T cell proliferation by the downregulation of Notch signaling [20]. In the course of dangerous infections, this mechanism can attenuate the immunosuppressive activity of MSCs and restore an efficient T cell response. Therefore, MSCs have more complicated effects on the immune system than the classical role as immune suppressor cells. By sensing their surrounding environment, MSCs are receptive to local biochemical signals and orchestrate the reprogramming of immune cells to promote host defense or resolve inflammation.
2.4. Clinical Application of MSCs in Humans

MSCs have great therapeutic potential for numerous diseases. More than 1000 registered clinical trials on the NIH Clinical Trial Database (http://clinicaltrials.gov/, accessed on 13 July 2022) were designed to evaluate MSCs therapy for a variety of human diseases [21]. As expected, a growing body of evidence for outcomes of MSC treatment in various diseases has been reported in the literature. It is presumable that diseases with optimal efficacy can fall into two main categories. One regards immune dysfunction and/or hyperinflammatory conditions, including autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus), inflammation diseases (Crohn’s disease, ulcerative colitis, ARDS), and graft failure or graft-versus-host disease after transplantation. The other involves tissue repair and regeneration, including degenerative diseases (osteoarthritis, degenerative disc disease, liver cirrhosis), traumatic injury (spinal cord injury, ischemic cardiomyopathy, cerebral infarction, burn wound, diabetic ulcer), congenital diseases (multiple sclerosis, osteogenesis imperfecta, muscular dystrophy), and bronchopulmonary dysplasia. The therapeutic benefits of MSCs appear to mainly involve immunomodulation and promotion of tissue repair/regeneration. In fact, MSCs may act via multiple mechanisms to achieve their therapeutic effects.

3. MSC Therapy in Preclinical Animal Models of ALI

3.1. Complexity of ALI Pathogenesis

A number of insults, infectious and noninfectious, can lead to the development of ALI. Characteristic features of ALI include loss of alveolar-capillary membrane integrity, excessive transepithelial leukocyte migration, and uncontrolled release of inflammatory mediators [22]. Following infection or trauma, upregulation in the production of proinflammatory cytokines occurs as the direct response and as a marker of ongoing pulmonary injury. Dysfunction of microvascular endothelial barriers causes an increase in capillary permeability, which permits the efflux of protein-rich fluid into pulmonary interstitium and distal airspaces. Excessive activation of neutrophils results in basement membrane destruction, increased permeability of the alveolar-capillary barriers, and release of damaging mediators to create ulcerating lesions in adjacent tissues. Alveolar epithelial cell damage contributes to the disruption of normal fluid transport, impairment in resolution of alveolar flooding, loss of surfactant production, and disorganization of tissue repair.

It is well recognized that uncontrolled pulmonary inflammation plays a key detrimental role in ALI, and the degree of acute inflammation and alveolar epithelial injury are highly associated with the outcome of human ALI [23]. There are a number of biomarkers proposed to predict the morbidity and mortality of ALI, including those found on the epithelium (von Willebrand factor) and endothelium (ICAM-1, surfactant protein D, and receptor for advanced glycation end-products), and those involving inflammation (IL-6 and IL-8) and coagulation (protein C and plasminogen activator inhibitor-1) [22].

3.2. Potential Mechanisms of MSCs in ALI: Focus on Molecular Biology

Advances in understanding the pathophysiology of ALI have led to investigations of numerous potential therapeutics. MSCs have generated a considerable interest in this field. The application of MSCs as cell therapy for ALI is suggested to alleviate pulmonary inflammation and injury, enhance pathogen clearance, maintain endothelial and epithelial function, and augment tissue repair [24].

MSCs are demonstrated to have higher engraftment efficiencies with sites of inflammation or injury [25]. Signaling factors released by injured tissues, such as stromal cell-derived factor-1 (SDF-1), platelet-derived growth factor, HGF, and monocyte chemoattractant protein-1 (MCP-1), serve as messages for MSC migration. In response to chemokine-attractive gradients generated by injured tissues, MSCs express a number of chemokine receptors on their surface, including CCR1, CCR2, CCR4, CCR5, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, and CXCR5 [26]. The communications between chemoattractive cytokines and their receptors enable MSCs to home to sites of injury and...
provide site-specific effects. Among them, the SDF-1/CXCR4 axis is frequently emphasized as an important pathway to control MSC migration and engraftment [27–30]. In addition, adhesion molecules on MSCs can interact directly with compromised endothelial cells in the lungs and participate in the maintenance of endothelial barrier integrity by preserving endothelial barrier proteins, such as VE-cadherin, claudin-1, and occludin-1 [31].

Excessive inflammation plays a key detrimental role in the development of ALI, and MSCs have profound immunomodulatory potential. It is rational to use MSCs as a temporary solution to downregulate hyperinflammatory reactions in ALI. In animal models of ALI, MSCs have been demonstrated to decrease production of proinflammatory cytokines (IL-1\(\alpha\), IL-1\(\beta\), IL-6, IL-8, MCP-1, MIP-2, IFN-\(\gamma\), and TNF-\(\alpha\)) and increase anti-inflammatory cytokines (IL-10) [24]. On the other hand, by which mechanisms MSCs suppress immune cells are further investigated. Corresponding to their broad immunomodulatory effects on immune cells, a variety of pathways are proposed. MSCs can reduce neutrophil migration into the alveoli as demonstrated by histopathology or MPO activity [32–36]. We documented that MSCs exert their immunomodulatory influence through down-regulation of MyD88-NF\(\kappa\)B signaling [35]. MSCs are reported to induce the generation and activation of Tregs for the balance of anti and proinflammatory factors [33]. TNF-\(\alpha\)-induced protein 6 (TNFAIP6/TSG-6) was highly induced in MSCs in response to lung injury and could cause a decrease in neutrophil accumulation and lung damage [37]. Increased intensity of PGE2 receptor, EP3, was found to correlate with the immunosuppressive activity of MSCs [38].

The beneficial effects of MSCs on the clearance of bacteria in ALI were demonstrated [36]. In the face of infection, MSCs can enhance phagocytosis and improve macrophage survival. Additionally, MSCs can produce substances with antibacterial activities. For example, cathelicidin LL-37 secreted by MSCs in response to bacterial challenge in ALI can cause disruption of bacterial membranes which is lethal to the microorganisms [39]. By upregulating the antibacterial protein lipocalin-2, MSCs were found to enhance bacterial clearance from the alveolar space in mice with bacterial pneumonia [40].

MSCs have great differentiation and regenerative capacities contributing to the repairment of injury tissues. A variety of factors secreted by MSCs, including keratinocyte growth factor, antiopoietin-1, HGF, and vascular endothelial growth factor, were demonstrated to improve alveolar fluid clearance, restore alveolar-capillary barrier and lung structure, and ultimately promote lung function recovery in ALI. Additionally, MSCs are able to reshape the pulmonary microenvironment by reducing the levels of profibrogenic factors, and the efficacy is associated with the correction of inappropriate endothelial/epithelial to mesenchymal transition [41].

3.3. Efficacy of MSC Therapy in Animals with ALI

Many studies were conducted to examine the efficacy of MSCs in animal models of ALI. ALI can be induced in experimental animals by infections, chemical injury, trauma, or pulmonary ischemia. Using lipopolysaccharides to induce ALI in rats or mice is the most common animal model, because it can mimic infectious ALI in humans and stimulate host immune responses. As for showing low immunogenic properties, using mismatched MSCs does not trigger proliferative T-cell response and rejection in the host. Therefore, MSC origins used in preclinical studies of ALI were diverse, syngeneic, allogeneic, or even xenogenic. The most common source of syngeneic MSCs was isolated from bone marrow; xenogenic MSCs were derived from human umbilical cords, adipose tissue, and bone marrow. The number of MSCs was usually around \(1 \times 10^6\) cells/kg per injection. However, a great diversity of treatment schedules was found in the literature.

McIntyre et al. performed a systematic meta-analysis of preclinical studies regarding MSC treatment in ALI [42]. They found that treatment with MSCs significantly decreases the overall odds of death in animals with ALI compared to untreated disease control animals (odds ratio, 0.24). MSCs were shown to reduce inflammation, enhance bacterial clearance, ameliorate organ damage, and improve survival. There were no significant short-term adverse effects observed. It is worth noting that their efficacy was maintained across
different types of animal models and means of ALI induction: MSC origin, source, route of administration and preparation; and clinical relevance of the model (the number and timing of MSC administration, supportive care strategies) [42]. As suggested by preclinical models, MSC-based therapy can be a potential modality for different types of ALI and provide supportive evidence for moving toward human clinical trials.

4. MSC Therapy in COVID-19

4.1. Pathogenesis of COVID-19

The pathogenesis of COVID-19 is complex. Through an interaction between the viral spike protein and the host angiotensin-converting enzyme 2 (ACE2) receptor, viral particles of SARS-CoV-2 can enter the target cell [43]. Owing to ACE2 receptors expressing on a variety of cells throughout the body, the clinical spectrum of COVID-19 can represent multiple organ involvement and not limit to pneumonia. Additionally, a diverse repertoire of membrane proteins can act as ACE2 cofactors or alternative receptors to allow the penetration of SARS-CoV-2 into various types of cells, even those not expressing ACE2 [44].

The host’s innate and adaptive immune responses are important to control viral spread and disease progression in COVID-19. The polyfunctional factors synthesized by SARS-CoV-2 can overcome the IFN-dependent processes of innate immunity, both the production of IFN-I-III and the subsequent transmission of secondary signals for the development of antiviral cellular stress. Suppression of IFN-I-III at the outset of COVID-19 is important for viral invasion, because IFN-I-III exhibit the greatest antiviral effectiveness in this period. In the majority of patients with severe symptoms of COVID-19, the antiviral immune-related IFN response is highly impaired [45]. It is interesting to note that IFNs play an ambiguous role in the respiratory tract in the face of infection. Effective initiation of IFN production in the upper airway leads to faster viral clearance and limits viral spread. Once invading pathogens escape from the immune control, the generation of IFN increases in the lungs which may contribute to the development of cytokine storm in the latter stages of COVID-19 [46]. SARS-CoV-2 infects alveolar macrophages and enhances the production of chemoattractants for Th1. Th1 cells can release IFN-γ, which can further promote the proinflammatory activities of monocytes and macrophages. The positive feedback loop drives persistent alveolar inflammation in COVID-19 [47].

SARS-CoV-2 infection can directly affect both the innate and adaptive immune systems, leading to disordered and chaotic immune responses. The proportions of dendritic cell compartments are significantly decreased in patients with COVID-19. An increase in levels of IFN-γ and TNF-α is associated with lymphocyte apoptosis in cytokine storm syndrome. Lymphopenia, which is significantly decreased in CD8+ T cells, CD4+ Th and Tregs in the blood, is noted in severe and critical patients [48]. On the contrary, the percentage of plasma B cells and B-cell clonality are increased. In patients with severe COVID-19, the immune landscape featured a deranged IFN-α response, profound immune exhaustion with skewed T cell receptor repertoire, and broad T cell expansion [49]. Of note, excessive production of proinflammatory cytokines, referred to as cytokine storm, is a critical phenomenon for patients with COVID-19 and is associated with disease severity, T cell depletion, systemic inflammation, and widespread tissue damage.

In mild and moderate patients with COVID-19, innate and adaptive immune responses are well-coordinated, contributing to the resolution of symptoms and convalescence. In contrast, in severe cases, uncontrolled inflammatory feedback loop triggers the formation of inflammatory cytokine storm which is one of the main features in severe COVID-19 and is associated with disease progression and severity. Many studies have been conducted to determine what inflammatory mediators are elevated in patients with COVID-19, and many inflammation-associated cytokines represent as candidates for measurement, such as IL-1β, IL-2, IL-6, IL-7, IL-12, IL-18, IL-33, IFN-α, IFN-γ, TNF-α, G-CSF, IFN-γ inducible protein 10, MCP-1, macrophage inflammatory protein 1-α, and TGF-β [50,51]. Results of the cytokine profiles in different studies may be inconsistent to some degree, and the
discrepancy may relate to many variables, including disease severity, baseline conditions of patients, time points of sample collection, therapeutic modalities, etc.

Pulmonary fibrosis is found as an important factor of long-term outcomes in patients with COVID-19. Acute inflammatory lesions in the lungs are generally resolved in the convalescence stage in the majority of patients with COVID-19. However, residual abnormalities on chest computed tomography scans, such as ground-glass opacity and strip-like fibrosis, can be found in about 40% of patients at 3 months after recovery and 25% at one year [52,53]. Fibrosis-related genes, including ACE2, TGFβ1, CTGF, and FN1, were found to increase transcription after the SARS-CoV-2 infection and induce lung fibrosis [54]. The process of endothelial/epithelial to mesenchymal transition may play a prominent role in the development of post-COVID-19 fibrosis [55]. Older patients with severe COVID-19 or ARDS might fare worse after the initial recovery from COVID-19 and have a higher risk of the persistent sequela of lung fibrosis.

4.2. Potential Mechanisms of MSC Therapy in COVID-19

The respiratory tract is usually the primary target organ of the SARS-CoV-2 infection, and many aspects in pathogenesis and clinical manifestations of COVID-19 have certain similarities with infectious ALI and ARDS. Autopsies of patients who died of critical COVID-19 showed the pathologic characteristics of pulmonary lesions, including diffuse alveolar damage, interstitial inflammatory cell infiltration, protein-rich exudates, hyaline membrane formation, endothelial cell membrane destruction, mural fibrosis, and microcystic honeycombing in the lungs [56–58]. These findings provide the rationality of MSC treatment for COVID-19 based on the results of preclinical models of ALI and clinical trials of ARDS [59], although the specific molecular mechanisms underlying therapeutic effects of MSCs require further research. Many factors involve disease progression in COVID-19, including direct viral toxicity, cell death, endothelial dysfunction, dysregulation of immune responses, and tissue fibrosis. As expected, the immunomodulatory, tissue repair, and antiviral and anti-fibrotic properties of MSCs signify their potential in the treatment of COVID-19.

ARDS caused by cytokine storm is the major cause of death in patients with COVID-19 [1]. Therefore, inhibition of cytokine storm may be the key in the management of patients with COVID-19. It is important to note that the formation of cytokine storm provides a hyperinflammatory microenvironment to trigger immunomodulation of MSCs. In turn, the powerful immunomodulatory capacity from MSCs may reduce or even eliminate the cytokine storm in COVID-19, and consequently improve outcomes. Nevertheless, the changes in inflammatory index profiles following MSC therapy were inconsistent, as previously described. On the other hand, the lung is the most predominant organ for MSC homing. Following administration, MSCs are primarily trapped in the capillary beds of the lungs. Although, MSCs are able to migrate to diverse sites during the development of the multi-organ injury and dysfunction accompanied by the existence of COVID-19 pneumonia. Indeed, MSCs are not only useful in treating COVID-19 pneumonia, but also have beneficial impacts on the extrapulmonary complications. Figure 2 summarizes the pathogenesis of COVID-19 and potential mechanisms of MSC therapy in COVID-19.

4.3. Clinical Efficacy of MSC Therapy in COVID-19

The safety and efficacy of transplanted MSCs for COVID-19 were evaluated in many clinical trials. As of June 2022, there were 95 clinical trials registered on the NIH Clinical Trial Database (http://clinicaltrials.gov/, accessed on 13 July 2022) when searching for “MSCs and COVID-19”. Registered trials of MSC therapy in COVID-19 with completed or recruiting status were summarized in Table 1 [21]. Currently, the majority of these trials were in phase I, I/II, or II. Around half of the trials were completed, but only a few have reported their results. Therefore, knowledge about this issue also has to be derived from reports on treating a small number of patients.
Figure 2. A schematic overview of the pathogenesis of COVID-19 and potential mechanisms of MSC therapy in COVID-19. In the acute phase, SARS-CoV-2 can synthesize polyfunctional factors and overcome the IFN-dependent processes in the upper airway. Once escaping from the immune control, SARS-CoV-2 can infect alveolar macrophages and enhance chemoattractant production for Th1. Th1 cells can release IFN-\(\gamma\) leading to further activation of monocytes and macrophages. The positive feedback loop plays an important role in the development of cytokine storm, which is a critical phenomenon of COVID-19 and is associated with lymphopenia, acute lung injury, and systemic inflammation. Multiple functions of MSCs involves in combating COVID-19. There is a dual effect of MSCs on regulating the immune system, enhancement of immune reactions to promote viral clearance and immunosuppression to alleviate cytokine storm. Along with direct antiviral activities and regenerative potential of tissue repair and anti-fibrosis, MSCs appear to be beneficial in COVID-19.

Nevertheless, current preliminary clinical results of MSC-based therapy show some favorable outcomes for severe and critically severe patients with COVID-19. A meta-analysis by Kirkham et al. demonstrated that the risk of death at the study endpoint is lower in patients receiving MSC therapy (risk ratio, 0.18), although follow-up differed [60]. Promising results regarding MSC therapy in COVID-19 included: (1) patients were well-tolerated without significant and severe adverse effects; (2) improvements were observed in clinical symptoms and pulmonary functions, such as oxygenation and PaO\(_2\)/FiO\(_2\) ratio; (3) downregulating cytokine storm by MSCs can be noted by decreasing circulating levels of proinflammatory cytokines and laboratory parameters (C-reactive protein, procalcitonin, ferritin, and D-dimer), increasing lymphocyte count, and resolving inflammatory lung lesions; (4) MSC-treated patients had a faster recovery time, a shorter hospital stay, and a lower mortality rate. According to the main goals of ongoing studies and trial reports, MSCs seem promising as an effective treatment option to alleviate the effects of COVID-19 [61].
### Table 1. Clinical trials of MSC-based therapies in COVID-19 registered on the NIH Clinical Trial Database.

| Registration ID | Title                                                                 | Phase | MSC Administration | MSC Source | Enrollment | Location | Status     |
|-----------------|----------------------------------------------------------------------|-------|--------------------|------------|------------|----------|------------|
| NCT04713878     | Mesenchymal stem cells therapy in patients with COVID-19 pneumonia   | -     | $1 \times 10^6$ /kg, iv, on days 0, 2, 4 | Unknown    | 21         | Turkey    | Completed  |
| NCT04898088     | A proof-of-concept study for the DNA repair driven by the mesenchymal stem cells in critical COVID-19 patients | -     | iv, three times with 30 days intervals | Unknown    | 30         | Turkey    | Completed  |
| NCT04611256     | Mesenchymal stem cells in patients diagnosed with COVID-19           | Phase 1 | $1 \times 10^6$ /kg, iv, once | AT         | 20         | Mexico    | Recruiting |
| NCT0436254      | Safety and efficacy study of allogeneic human dental pulp mesenchymal stem cells to treat severe COVID-19 patients | Phase 1/2 | $2 \times 10^7$ /kg, iv, on days 1, 4, 7 | Dental pulp | 20         | China     | Recruiting |
| NCT04288102     | Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19) | Phase 2 | $4 \times 10^7$ /kg, iv, on days 0, 3, 6 | UC         | 100        | China     | Completed  |
| NCT04349631     | A clinical trial to determine the safety and efficacy of Hope Biosciences autologous mesenchymal stem cell therapy (HB-adMSCs) to provide protection against COVID-19 | Phase 2 | iv, 5 times | HB-adMSCs (AT) | 56         | USA       | Completed  |
| NCT04905836     | Study of allogeneic adipose-derived mesenchymal stem cells for treatment of COVID-19 acute respiratory distress | Phase 2 | $1 \times 10^6$ /kg, iv, on days 0, 2, 4 | COVI-MSC (AT) | 60         | USA       | Recruiting |
| NCT04348435     | A randomized, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of Hope Biosciences allogeneic mesenchymal stem cell therapy (HB-adMSCs) to provide protection against COVID-19 | Phase 2 | $5 \times 10^7$ /kg, iv, on weeks 0, 2, 6, 10, 14 | HB-adMSCs (AT) | 55         | USA       | Completed  |
| NCT04625738     | Efficacy of infusions of MSC from Wharton jelly in the SARS-CoV-2 (COVID-19) related acute respiratory distress syndrome | Phase 2 | $1 \times 10^6$ /kg on days 0 and $0.5 \times 10^6$ /kg iv, on days 3, 3 | UC         | 30         | France    | Completed  |
| NCT05132972     | Allogenic UCMSCs as adjuvant therapy for severe COVID-19 patients     | Phase 2/3 | $1 \times 10^6$ /kg, iv, on days 0, 3, 6 | UC         | 42         | Indonesia | Recruiting |
| NCT04573270     | Mesenchymal stem cells for the treatment of COVID-19                   | Phase 1 | Single dose, iv     | UC         | 40         | USA       | Completed  |
| NCT04382547     | Treatment of COVID-19 associated pneumonia with allogeneic pooled olfactory mucosa-derived mesenchymal stem cells | Phase 1/2 | NP               | Olfactory mucosa | 32         | Belarus   | Completed  |
| NCT04355728     | Use to UC-MSCs for COVID-19 patients                                  | Phase 1/2 | $1 \times 10^6$ /kg, iv, on days 1, 3 | UC         | 24         | USA       | Completed  |
| NCT04888949     | A study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 infection (COVID-19) | Phase 2 | $1 \times 10^6$ /kg, iv, once a week, total 4 times | AT         | 20         | Japan     | Recruiting |
| NCT04362189     | Efficacy and safety study of allogeneic HB-adMSCs for the treatment of COVID-19 | Phase 2 | $1 \times 10^6$ /kg, iv, on days 0, 3, 7, 10 | HB-adMSC (AT) | 53         | USA       | Terminated |
| NCT04535856     | Therapeutic study to evaluate the safety and efficacy of DW-MSC in COVID-19 patients | Phase 1 | $1 \times 10^7$ /kg or $1 \times 10^6$ /kg, iv, once | DW-MSC     | 9          | Indonesia | Completed  |
| NCT04565665     | Cord blood-derived mesenchymal stem cells for the treatment of COVID-19 related acute respiratory distress syndrome | Phase 1 | iv               | Cord blood | 70         | USA       | Recruiting |

**Note:** The table includes information on the registration ID, title, phase, MSC administration, MSC source, enrollment, location, and status for each clinical trial.
Table 1. Cont.

| Registration ID | Title                                                                 | Phase     | MSC Administration | MSC Source | Enrollment | Location | Status    |
|-----------------|----------------------------------------------------------------------|-----------|--------------------|------------|------------|----------|-----------|
| NCT04903327     | Study of intravenous COVI-MSC for treatment of COVID-19-induced acute respiratory distress | Phase 2   | $1 \times 10^6$/kg, iv, on days 0, 2, 4 | COVI-MSC (AT) | 100        | Brazil   | Recruiting |
| NCT05433298     | Mesenchymal stem cells for the treatment of patients with COVID-19    | Phase 1/2 | $1 \times 10^6$/kg, iv, once     | UC         | 60         | Brazil   | Recruiting |
| NCT04366323     | Clinical trial to assess the safety and efficacy of intravenous administration of allogeneic adult mesenchymal stem cells of expanded adipose tissue in patients with severe pneumonia due to COVID-19 | Phase 1/2 | $8 \times 10^6$/kg, iv, two doses | AT         | 26         | Spain    | Completed  |
| NCT04629105     | Regenerative medicine for COVID and flu-elicited ARDS using Lomecel-B | Phase 1   | $1 \times 10^6$/kg, iv, three doses | Lomecel-B   | 70         | USA      | Recruiting |
| NCT04494386     | Umbilical cord lining stem cells (ULSC) in patients with COVID-19    | Phase 1/2 | $1 \times 10^6$/kg, iv, once     | UC         | 60         | USA      | Recruiting |
| NCT04790685     | A phase II study in patients with moderate to severe ARDS due to COVID-19 | Phase 2   | NP                  | BM         | 40         | USA      | Recruiting |
| NCT04345601     | Mesenchymal stromal cells for the treatment of SARS-CoV-2 induced acute respiratory failure (COVID-19 Disease) | Phase 1/2 | $1 \times 10^6$/kg, iv, once     | BM         | 30         | USA      | Recruiting |
| NCT04522986     | An exploratory study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 Infection (COVID-19) | Phase 1   | $1 \times 10^6$/kg, iv, once a week, total 4 times | AT         | 6          | Japan    | Completed  |
| NCT05126563     | Randomized double-blind phase 2 study of allogeneic HB-adMSCs for the treatment of chronic post-COVID-19 syndrome | Phase 2   | iv, on weeks 0, 2, 6, 10          | HB-adMSCs (AT) | 80        | USA      | Recruiting |
| NCT04392778     | Clinical use of stem cells for the treatment of COVID-19             | Phase 1/2 | $1 \times 10^6$/kg, iv, on days 0, 3, 6 | UC         | 30         | Turkey   | Completed  |
| NCT04361942     | Treatment of severe COVID-19 pneumonia with allogeneic mesenchymal stromal cells (COVID_MSV) | Phase 2   | $1 \times 10^6$/kg, iv, once     | BM         | 24         | Spain    | Completed  |
| NCT03042143     | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) | Phase 1/2 | $4 \times 10^6$/kg, iv, once     | UC         | 75         | United Kingdom | Recruiting |
| NCT04400032     | Cellular immuno-therapy for COVID-19 acute respiratory distress syndrome | Phase 1   | $2.5 \times 10^6$/kg or $5 \times 10^7$/kg or $9 \times 10^7$/kg, iv, three times | BM         | 9          | Canada   | Completed  |
| NCT04333368     | Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS | Phase 1/2 | $1 \times 10^6$/kg, iv, on days 1, 3, 5 | UC         | 47         | France   | Completed  |
| NCT05286255     | Mesenchymal stromal cells for COVID-19 and viral pneumonias          | Phase 1   | iv, on days 1, 3               | UC         | 10         | USA      | Recruiting |

AT: adipose tissue; BM: bone marrow; iv: intravenous injection; MSC: mesenchymal stem cell; NP: not provided; UC: umbilical cord.
5. Issues Related to Clinical Application of MSCs in COVID-19

5.1. Potential Risks of MSC Therapy

Despite a growing body of evidence suggesting the safety of MSC therapy, MSC administration is not completely free of risks. Adverse events include infusion reactions, allergic reactions, secondary infections, viral reactivation, and thromboembolic events.

A number of questions need to be answered regarding optimal manufacturing and the quality of MSCs for clinical use. In the management of acute indications such as COVID-19, cryobanking may remain a prerequisite. Because the number of MSCs obtained from the donor is usually insufficient for use and MSCs have a great propensity for in vitro expansion, passaged cells are used extensively in clinical practice. In vitro expansion of MSCs may be associated with genetic instability and changes in cell behavior. This highlights the importance of guaranteeing conditions for MSC culture, using cells without extensive population doublings, and monitoring the karyotyping of MSCs. On the other hand, the use of cryopreserved MSC products, which commonly contain dimethyl sulfoxide, may cause acute toxicity syndrome, such as skin reactions, headache, dizziness, nausea, vomiting, and allergic reactions. Premedication with antihistamines can prevent or alleviate these symptoms.

The risk of secondary infection is potentiated by the use of fresh products. The risk of herpesvirus transmission by transplantation of MSCs from healthy seropositive donors is low, because no viral DNA was detected in MSCs. However, MSCs may be susceptible to infection if infused into patients with viremia based on the in vitro finding that cytopathological effects and intracellular viral antigens can be found in MSCs after infection of cytomegalovirus and herpes simplex virus type 1 [62]. In addition, there is also a theoretical possibility that a state of immunosuppression induced by MSCs would allow pathogens to evade the immune response, especially in critically ill patients.

5.2. Optimal Treatment Protocols

Many issues related to the application of MSCs should be further explored, and consensus and guidelines are required to maximize their therapeutic efficacy. For example, the choice of a time window for MSC administration can directly affect treatment efficacy. Early initiation of MSC treatment is associated with a higher extubation rate in patients receiving mechanical ventilation. Furthermore, MSC transfusion for severe patients prior to intubation was found to reduce the risk of disease progression and mortality [41].

In the clinical trials registered in the treatment of COVID-19, MSCs derived from umbilical cords were used most frequently, followed by adipose tissue (Table 1). In our experience, UCMSCs could promote hematopoietic engraftment after hematopoietic stem cell transplantation [63,64] and treat refractory graft-versus-host disease, bronchopulmonary dysplasia, and COVID-19 effectively and safely [65,66]. Cryopreserved UCMSC products from MSC banks have great advantages over fresh products to treat COVID-19 in terms of their feasibility for clinical application and off-the-shelf availability, because they are fully characterized and confirmed sterile before infusion. Typically, these products are transported and thawed at the bedside, and it is convenient for clinical utility.

Intravenous administration has been the most utilized route of administration. Following intravenous administration, a majority of delivered MSCs rapidly reach the lungs and lodge in the pulmonary vascular bed. MSCs may enter directly to reach a higher concentration in the lungs via intratracheal administration. However, its use restrained by the poor feasibility of administering fluids to hypoxemic patients. Of most importance, the risk of environmental contamination with aerosols should be seriously considered in the management of patients with infectious diseases, such as COVID-19. There is little controversy that administration of MSCs intravenously is feasible to treat COVID-19 and is much safer for the environment and care providers.

As shown in Table 1, MSCs were administrated a single time or in multiples, and the doses ranged from $0.5 \times 10^6$ to $4 \times 10^8$ cells/kg per injection. A dose of $1 \times 10^6$ cells/kg per injection was most commonly used. In vitro, we found that the immunosuppressive
effects increased with the increasing cell dose of MSCs in a dose-dependent manner [65]. It has yet to be determined whether the therapeutic effects also increase when infusing more MSCs. Additionally, the risk of thromboembolism may be increased if too many cells are infused once a time. A higher dose of MSCs may be needed to treat critically ill patients with COVID-19, but high doses greater than $12 \times 10^6$ cells/kg should be used with caution [67]. Tracking studies using labeled MSCs demonstrate that most MSCs are cleared within 48 h. MSCs appear to act as a hit-and-run attack, and therefore multiple injections may be needed to achieve efficient effects. The injection interval of 3 days may be feasible for the acute phase in COVID-19.

6. Conclusions

MSC therapy brings hope to combating COVID-19 during a global pandemic. The general mechanisms of action include immunomodulatory function, tissue repair enhancement, and antiviral activities. Current preliminary results have shown some favorable outcomes for severe and critically severe patients with COVID-19. However, a variety of challenges related to its use still lay ahead. Further studies are warranted.

Author Contributions: Conceptualization, K.-H.W. and Y.-H.C.; writing-original draft, J.-P.L. and Y.-H.C.; writing-review and editing, W.-R.C., Y.-J.L. and S.-F.Y.; supervision, Y.-H.C. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Ministry of Science and Technology (MOST 110-2314-B-040-012).

Conflicts of Interest: The authors declared no conflict of interest.

Abbreviations

ACE2: angiotensin-converting enzyme 2, ALI: acute lung injury, ARDS: acute respiratory distress syndrome, COVID-19: coronavirus disease 2019, HGF: hepatocyte growth factor, IFN-γ: interferon-γ, MCP-1: monocyte chemoattractant protein-1, MSCs: mesenchymal stem cells, PD-1: programmed cell death protein 1, PGE2: prostaglandin E2, Treg: regulatory T cell, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, SDF-1: stromal cell-derived factor-1, TGF-β1: transforming growth factor-β1, TLRs: Toll-like receptors, TNF-α: tumor necrosis factor-α, UCMSCs: umbilical cord-derived MSCs.

References

1. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [CrossRef] [PubMed]
2. Friedenstein, A.J.; Piatetzky-Shapiro, I.I.; Petrakova, K.V. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 1966, 16, 381–390. [CrossRef] [PubMed]
3. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317. [CrossRef] [PubMed]
4. Wexler, S.A.; Donaldson, C.; Denning-Kendall, P.; Rice, C.; Bradley, B.; Hows, J.M. Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not. Br. J. Haematol. 2003, 121, 368–374. [CrossRef]
5. Secco, M.; Zucconi, E.; Vieira, N.M.; Fogaca, L.L.; Cerqueira, A.; Carvalho, M.D.; Jazedje, T.; Okamoto, O.K.; Muotri, A.R.; Zatz, M. Multipotent stem cells from umbilical cord: Cord is richer than blood! Stem Cells 2008, 26, 146–150. [CrossRef]
6. Chan, C.K.; Wu, K.H.; Lee, Y.S.; Hwang, S.M.; Lee, M.S.; Liao, S.K.; Cheng, E.H.; See, L.C.; Tsai, C.N.; Kuo, M.L.; et al. The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSCs, and adult-type MSCs. Transplantation. Transplantation 2012, 94, 132–138. [CrossRef]
7. Zhang, Z.Y.; Teoh, S.H.; Chong, M.S.K.; Schantz, J.T.; Fisk, N.M.; Choolani, M.A.; Chan, J. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells 2009, 27, 126–137. [CrossRef]
8. Ostrand-Rosenberg, S.; Horn, L.A.; Haile, S.T. The programmed death-1 immune-suppressive pathway: Barrier to antitumor immunity. J. Immunol. 2014, 193, 3835–3841. [CrossRef]
9. Strasser, A.; Jost, P.J.; Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30, 180–192. [CrossRef]
10. Ramasamy, R.; Fazelekova, H.; Lam, E.W.F.; Soeiro, I.; Lombardi, G.; Dazzi, F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. *Transplantation* 2007, 83, 71–76. [CrossRef]

11. Deng, Y.; Zhang, Y.; Ye, L.; Zhang, T.; Cheng, J.; Chen, G.; Zhang, Q.; Yang, Y. Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. *Sci. Rep.* 2016, 6, 37566. [CrossRef] [PubMed]

12. Luz-Crawford, P.; Djouad, F.; Toupet, K.; Bony, C.; Franquessa, M.; Hoogduijn, M.J.; Jorgensen, C.; Noel, D. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. *Stem Cells* 2016, 34, 483–492. [CrossRef] [PubMed]

13. Melief, S.M.; Schrama, E.; Brugman, M.H.; Tiemessen, M.M.; Hoogduijn, M.J.; Fibbe, W.E.; Roelofs, H. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. *Stem Cells* 2013, 31, 1980–1991. [CrossRef] [PubMed]

14. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D.; Cappiello, V.; Cazzanti, F.; Riso, M.; Gualandi, F.; Mancardi, G.L.; Pistoia, V.; et al. Human mesenchymal stem cells modulate B-cell functions. *Blood* 2006, 107, 367–372. [CrossRef]

15. Davies, I.C.; Heldring, N.; Kadri, N.; Le Blanc, K. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. *Stem Cells* 2017, 35, 766–776. [CrossRef]

16. Ge, W.; Jiang, J.; Arp, J.; Liu, W.; Garcia, B.; Wang, H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxgenase expression. *Transplantation* 2010, 90, 1312–1320. [CrossRef]

17. Ghannam, S.; Fene, J.; Moquet-Torcy, G.; Jorgensen, C.; Yssel, H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. *J. Immunol.* 2010, 185, 302–312. [CrossRef]

18. Wang, W.B.; Yen, M.L.; Liu, K.J.; Hsu, P.J.; Lin, M.H.; Chen, P.M.; Sudhir, P.R.; Chen, C.H.; Sytwud, H.K.; et al. Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. *Stem Cell Rep.* 2015, 5, 392–404. [CrossRef]

19. Li, W.; Ren, G.; Huang, Y.; Su, J.; Han, Y.; Li, J.; Chen, X.; Cao, K.; Chen, Q.; Shou, P.; et al. Mesenchymal stem cells: A double-edged sword in regulating immune responses. *Cell Death Differ.* 2012, 19, 1505–1513. [CrossRef]

20. Liotta, F.; Angeli, R.; Cosmi, L.; Fili, L.; Manuelli, C.; Frosali, F.; Mazzinghi, B.; Maggi, L.; Pasini, A.; Lisi, V.; et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. *Stem Cells* 2008, 26, 279–289. [CrossRef]

21. U.S. National Library of Medicine. ClinicalTrials.gov. Available online: http://clinicaltrials.gov/ (accessed on 13 July 2022).

22. Johnson, E.R.; Matthay, M.A. Acute lung injury: Epidemiology, pathogenesis, and treatment. *J. Aerosol. Med. Pulm. Drug Deliv.* 2010, 23, 243–252. [CrossRef] [PubMed]

23. Ware, L.B.; Koyama, T.; Billheimer, D.D.; Wu, W.; Bernard, G.R.; Thompson, B.T.; Brower, R.G.; Standiford, T.J.; Martin, T.R.; Matthay, M.A.; et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. *Crit. Care* 2010, 137, 288–296. [CrossRef] [PubMed]

24. Xu, F.; Hu, Y.; Zhou, J.; Wang, X. Mesenchymal stem cells in acute lung injury: Are they ready for translational medicine? *J. Cell Mol. Med.* 2013, 17, 927–935. [CrossRef]

25. Karp, J.M.; Leng Teo, G.S. Mesenchymal stem cell homing: The devil is in the details. *Cell Stem Cell* 2009, 4, 206–216. [CrossRef]

26. Ringe, J.; Strassburg, S.; Neumann, K.; Endres, M.; Notter, M.; Burmester, G.R.; Kaps, C.; Sittinger, M. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL12 but not CCL2. *J. Cell Biochem.* 2007, 101, 135–146. [CrossRef]

27. Bobis-Wozowicz, S.; Miekus, K.; Wybieralska, E.; Jarocha, D.; Zawisz, A.; Madeja, Z.; Majka, M. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. *Exp. Hematol.* 2011, 39, 686–696.e4. [CrossRef]

28. Sordi, V. Mesenchymal stem cell homing capacity. *Transplantation* 2009, 87, S42–S45. [CrossRef]

29. Shi, M.; Li, J.; Liao, L.; Chen, B.; Li, B.; Chen, L.; Jia, H.; Zhao, R.C. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. *Haematologica* 2007, 92, 897–904. [CrossRef]

30. Wynn, R.F.; Hart, C.A.; Corradi-Perini, C.; O’Neill, L.; Evans, C.A.; Wraith, J.E.; Fairbairn, L.J.; Bellantuono, I. A small proportion of mesenchymal stem cells associate with indoleamine 2,3-dioxygenase expression. *Blood* 2004, 104, 1980–1991. [CrossRef] [PubMed]

31. Pati, S.; Gerber, M.H.; Menge, T.D.; Wataha, K.A.; Zhao, Y.; Baumgartner, J.A.; Zhao, J.; Letourneau, P.A.; Huby, M.P.; Baer, L.A.; et al. Bone marrow derived mesenchymal stem cells induce human regulatory T cells by secreting IL1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. *Stem Cells* 2013, 31, 1980–1991. [CrossRef] [PubMed]

32. Zhang, S.; Danchuk, S.D.; Imhof, K.M.; Semon, J.A.; Scruggs, B.A.; Bonvillain, R.W.; Strong, A.L.; Gimble, J.M.; Betancourt, A.M.; Sullivan, D.E.; et al. Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury. *Stem Cell Res. Ther.* 2013, 4, 13. [CrossRef] [PubMed]

33. Sun, J.; Han, Z.-B.; Liao, W.; Yang, S.G.; Yang, Z.; Yu, J.; Meng, L.; Wu, R.; Han, Z.C. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Box3 (FOX3)+ regulatory T cells and balancing anti- and pro-inflammatory factors. *Cell Physiol. Biochem.* 2011, 27, 587–596. [CrossRef] [PubMed]

34. Li, J.; Li, D.; Liu, X.; Tang, S.; Wei, F. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. *J. Inflamm.* 2012, 9, 33. [CrossRef] [PubMed]
35. Wu, K.H.; Li, J.P.; Chao, W.R.; Lee, Y.J.; Yang, S.F.; Cheng, C.C.; Chao, Y.H. Immunomodulation via MyD88-NFκB signaling pathway from human umbilical cord-derived mesenchymal stem cells in acute lung injury. *Int. J. Mol. Sci.* 2022, 23, 5295. [CrossRef]

36. Kim, E.S.; Chang, Y.S.; Choi, S.J.; Kim, J.K.; Yoo, H.S.; Ahn, S.Y.; Sung, D.K.; Kim, S.Y.; Park, Y.R.; Park, W.S. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. *Respir. Res.* 2011, 12, 108. [CrossRef]

37. Danchuk, S.; Ylostalo, J.H.; Hossain, F.; Sorge, R.; Ramsey, A.; Bonvillain, R.W.; Lasky, J.A.; Bunnell, B.A.; Welsh, D.A.; Prockop, D.J.; et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. *Stem Cell Res. Ther.* 2011, 2, 27. [CrossRef]

38. Yilmaz, S.; Inandiklioglu, N.; Yildizdas, D.; Subasi, C.; Acikalin, A.; Kuyucu, Y.; Bayram, I.; Topak, A.; Tanyeli, A.; Duruksu, G.; et al. Mesenchymal stem cell: Does it work in an experimental model with acute respiratory distress syndrome? *Stem Cell Rev. Rep.* 2013, 9, 80–92. [CrossRef]

39. Nijnik, A.; Hancock, R.E. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. *Curr. Opin. Hematol.* 2009, 16, 41–47. [CrossRef]

40. Gupta, N.; Krasnodembskaya, A.; Kapetanaki, M.; Mouded, M.; Tan, X.; Serikov, V.; Matthay, M.A. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. *Thorax* 2012, 67, 533–539. [CrossRef]

41. Xu, R.; Feng, Z.; Wang, F.S. Mesenchymal stem cell treatment for COVID-19. *EBioMedicine* 2021, 77, 103920. [CrossRef]

42. McIntyre, R.A.; Morales-Nebreda, L.; Markov, N.S.; Swaminathan, S.; Querrey, M.; Guzman, E.R.; Abbott, D.A.; Donnelly, H.K.; Griffin, E.; Grimshaw, J.; et al. Efficacy of mesenchymal stem cell therapy for acute lung injury: A systematic review. *PloS ONE* 2016, 11, e0147170. [CrossRef] [PubMed]

43. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020, 367, 1444–1448. [CrossRef] [PubMed]

44. Gusev, E.; Sarapultsev, A.; Solomatinia, L.; Chereshnev, V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. *Int. J. Mol. Sci.* 2022, 23, 2. [CrossRef] [PubMed]

45. Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Pere, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 2020, 369, 718–724. [CrossRef] [PubMed]

46. Gusev, E.; Sarapultsev, A.; Hu, D.; Chereshnev, V. Problems of pathogenesis and pathogenetic therapy of COVID-19 from the perspective of the general theory of pathological systems (general pathological processes). *Int. J. Mol. Sci.* 2021, 22, 15. [CrossRef]

47. Grant, R.A.; Morales-Nebrada, L.; Markov, N.S.; Swaminathan, S.; Querrey, M.; Guzman, E.R.; Abbott, D.A.; Donnelly, H.K.; Donayre, A.; Goldberg, I.A.; et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature* 2021, 1, 635–641. [CrossRef]

48. Wang, F.; Nie, J.; Wang, H.; Zhao, Q.; Xiong, Y.; Deng, L.; Song, S.; Ma, Z.; Mo, P.; Zhang, Y. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J. Infect. Dis.* 2020, 221, 1762–1769. [CrossRef]

49. Zhang, J.Y.; Wang, X.M.; Xing, X.; Xu, Z.; Zhang, C.; Song, J.W.; Fan, X.; Xia, P.; Fu, J.L.; Wang, S.Y.; et al. Single-cell landscape of immunological responses in patients with COVID-19. *Nat. Immunol.* 2020, 21, 1107–1118. [CrossRef]

50. Ciccioppo, R.; Gibellini, D.; Astori, G.; Bernardi, M.; Bozza, A.; Chiaregato, K.; Elice, F.; Ugel, S.; Caligola, S.; De Sanctis, F.; et al. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. *Stem Cell Res. Ther.* 2021, 12, 316. [CrossRef]

51. Kavianpour, M.; Saleh, M.; Verdi, J. The role of mesenchymal stromal cells in immune modulation of COVID-19: Focus on cytokine storm. *Stem Cell Res. Ther.* 2020, 11, 404. [CrossRef]

52. Zhou, M.; Xu, J.; Liao, T.; Yin, Z.; Yang, F.; Wang, K.; Wang, Z.; Yang, D.; Wang, S.; Peng, Y.; et al. Comparison of residual pulmonary abnormalities 3 months after discharge in patients who recovered from COVID-19 of different severity. *Front. Med. (Lausanne)* 2021, 8, 682087. [CrossRef] [PubMed]

53. Pan, F.; Yang, L.; Liang, B.; Ye, T.; Li, L.; Li, L.; Liu, D.; Wang, J.; Hesketh, R.L.; Zheng, C. Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19. *Radiology* 2020, 322, 709–719. [CrossRef] [PubMed]

54. Xu, J.; Xu, X.; Jiang, L.; Dua, K.; Hansbro, P.M.; Liu, G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. *Respir. Res.* 2020, 21, 182. [CrossRef] [PubMed]

55. Eapen, M.S.; Lu, W.; Gaikwad, A.V.; Bhattarai, P.; Chia, C.; Hardiker, A.; Haug, G.; Sohal, S.S. Endothelial to mesenchymal transition: A precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? *Eur. Respir. J.* 2020, 56, 2003167. [CrossRef] [PubMed]

56. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 2020, 8, 420–422. [CrossRef]

57. Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R.S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo, R.; Antinori, S.; Corbellino, M.; et al. Pulmonary post-mortem findings in a series of 23 COVID-19 cases from northern Italy: A two-centre descriptive study. *Lancet Infect. Dis.* 2020, 20, 1135–1140. [CrossRef]

58. Shi, L.; Wang, L.; Xu, R.; Zhang, C.; Xie, Y.; Liu, K.; Li, T.; Hu, W.; Zhen, C.; Wang, F.S. Mesenchymal stem cell therapy for severe COVID-19. *Signal Transduct. Target. Ther.* 2021, 6, 339. [CrossRef]
59. Qu, W.; Wang, Z.; Hare, J.M.; Bu, G.; Malles, J.M.; Pascual, J.M.; Caplan, A.I.; Kurtzberg, J.; Zubair, A.C.; Kubrova, E.; et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. *Stem Cells Transl. Med.* **2020**, *9*, 1007–1022. [CrossRef]

60. Kirkham, A.M.; Monaghan, M.; Bailey, A.J.; Shorr, R.; Lalu, M.M.; Fergusson, D.A.; Allan, D.S. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19. *Cytotherapy* **2022**, *24*, 639–649. [CrossRef]

61. Sengul, F.; Ozturk, B.; Vatansev, H. Mesenchymal stem cell therapy for COVID-19. *Am. J. Stem Cells* **2021**, *10*, 79–89.

62. Sundin, M.; Orvell, C.; Rasmusson, I.; Sundberg, B.; Ringden, O.; Le Blanc, K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. *Bone Marrow Transplant.* **2006**, *37*, 1051–1059. [CrossRef] [PubMed]

63. Chao, Y.H.; Tsai, C.; Peng, C.T.; Wu, H.P.; Chan, C.K.; Weng, T.; Wu, K.H. Cotransplantation of umbilical cord MSCs to enhance engraftment of hematopoietic stem cells in patients with severe aplastic anemia. *Bone Marrow Transplant.* **2011**, *46*, 1391–1392. [CrossRef] [PubMed]

64. Wu, K.H.; Tsai, C.; Wu, H.P.; Sieber, M.; Peng, C.T.; Chao, Y.H. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: Enhance hematopoiesis after cord blood transplantation. *Cell Transplant.* **2013**, *22*, 2041–2051. [CrossRef] [PubMed]

65. Wu, K.H.; Chan, C.K.; Tsai, C.; Chang, Y.H.; Sieber, M.; Chiu, T.H.; Ho, M.; Peng, C.T.; Wu, H.P.; Huang, J.L. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. *Transplantation* **2011**, *91*, 1412–1416. [CrossRef] [PubMed]

66. Su, B.H.; Wu, K.H.; Lin, H.Y.; Lin, M.H.; Peng, C.T.; Tsai, C. Umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia. *Pediatrics* **2011**, *126*, 1127–1133.

67. Galipeau, J.; Sensebe, L. Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. *Cell Stem Cell* **2018**, *22*, 824–833. [CrossRef]